On December 27th, Sanofi announced on its official WeChat account that its rosuvastatin ezetimibe tablets (I) have been approved by the National Medical Products Administration of China for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) patients. It is reported that as the first approved single tablet compound formulation of rosuvastatin and ezetimibe in China, one tablet administration can achieve a reduction of over 50% in low-density lipoprotein cholesterol (LDL-C).